Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2014 | Original Article

The association of ¹⁸F-FDG PET/CT parameters with survival in malignant pleural mesothelioma

Authors: Astero Klabatsa, Sugama Chicklore, Sally F. Barrington, Vicky Goh, Loic Lang-Lazdunski, Gary J. R. Cook

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2014

Abstract

Purpose

Malignant pleural mesothelioma (MPM) is a disease with poor prognosis despite multimodal therapy but there is variation in survival between patients. Prognostic information is therefore potentially valuable in managing patients, particularly in the context of clinical trials where patients could be stratified according to risk. Therefore we have evaluated the prognostic ability of parameters derived from baseline 2-[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT).

Methods

In order to determine the relationships between metabolic activity and prognosis we reviewed all ¹⁸F-FDG PET/CT scans used for pretreatment staging of MPM patients in our institution between January 2005 and December 2011 (n = 60) and measured standardised uptake values (SUV) including mean, maximum and peak values, metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Overall survival (OS) or time to last censor was recorded, as well as histological subtypes.

Results

Median follow-up was 12.7 months (1.9–60.9) and median OS was 14.1 months (1.9–54.9). By univariable analysis histological subtype (p = 0.013), TLG (p = 0.024) and MTV (p = 0.038) were significantly associated with OS and SUV_max was borderline (p = 0.051). On multivariable analysis histological subtype and TLG were associated with OS but at borderline statistical significance (p = 0.060 and 0.058, respectively). No statistically significant differences in any PET parameters were found between the epithelioid and non-epithelioid histological subtypes.

Conclusion

¹⁸F-FDG PET/CT parameters that take into account functional volume (MTV, TLG) show significant associations with survival in patients with MPM before adjusting for histological subtype and are worthy of further evaluation to determine their ability to stratify patients in clinical trials.

Brown T, Darnton A, Fortunato L, Rushton L, British Occupational Cancer Burden Study Group. Occupational cancer in Britain. Respiratory cancer sites: larynx, lung and mesothelioma. Br J Cancer 2012;107:S56–70.PubMedCentralPubMedCrossRef

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685–94.PubMedCentralPubMedCrossRef

Cao C, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692–703.PubMedCrossRef

Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496–507.PubMedCrossRef

Scott AM. Current status of positron emission tomography in oncology. Int Med J 2001;31:27–36.CrossRef

Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241–5.PubMed

Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49:S27–32.PubMedCrossRef

Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005;129:1364–70.PubMedCrossRef

Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000;120:128–33.PubMedCrossRef

10.

Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:806–11.PubMedCrossRef

11.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–50S.PubMedCentralPubMedCrossRef

12.

Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, et al. Phantom study on radiotherapy planning using PET/CT–delineation of GTV by evaluating SUV. J Radiat Res 2010;51:157–64.PubMedCrossRef

13.

Boucek J, Francis RJ, Green AJ. Automated approach to identification and quantitation of tumour volumes in chemotherapy monitoring using FDG PET. J Nucl Med 2005;46:464P.

14.

Lang-Lazdunski L, Bille A, Lal R, Crane P, McLean E, Landau D, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737–43.PubMedCrossRef

15.

Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer 2012;48:1244–54.PubMedCrossRef

16.

Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol 2009;11:473–9.PubMedCrossRef

17.

Genestreti G, Moretti A, Piciucchi S, Tiseo M, Bersanelli M, Scarlattei M, et al. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. Technol Cancer Res Treat 2012;11:163–7.PubMed

18.

Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409–17.PubMedCrossRef

19.

Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449–58.PubMedCrossRef

20.

Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007;11:961–9.PubMedCrossRef

21.

Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999;2:159–71.PubMedCrossRef

22.

Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. Eur J Radiol 2012;81:e19–25.PubMedCrossRef

23.

Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010;67:311–7.PubMedCrossRef

24.

Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010;17:2787–94.PubMedCrossRef

25.

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, et al. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol 2012;7:1192–7.PubMedCentralPubMedCrossRef

26.

Genestreti G, Moretti A, Piciucchi S, Giovannini N, Galassi R, Scarpi E, et al. FDG PET/CT response evaluation in malignant pleural mesothelioma patients treated with talc pleurodesis and chemotherapy. J Cancer 2012;3:241–5.PubMedCentralPubMedCrossRef

27.

Pleural mesothelioma. In: Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 271–7.

Title: The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
Authors: Astero Klabatsa
Sugama Chicklore
Sally F. Barrington
Vicky Goh
Loic Lang-Lazdunski
Gary J. R. Cook
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2561-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The association of ¹⁸F-FDG PET/CT parameters with survival in malignant pleural mesothelioma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Erratum to: Twins in spirit: DOTATATE and high-affinity DOTATATE

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT

Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP

Imaging acute spinal myelitis with 18F-FDG PET/CT

Retraction Note: Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging

Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study